Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E, NASH CRN. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology 2016 Dec;151(6):1141-1154.e9. Epub 2016 Aug 26.

PubMed ID: 27569726
Public Release Type: Journal
Publication Year: 2016
Affiliation: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
DOI: https://doi.org/10.1053/j.gastro.2016.08.027
Authors: Schwimmer JB, Sanford J, Paiz M, Newton K, Middleton M, Durelle J, Bross C, Behling C, Awai H, Arroyo S, Angeles J, Africa J, Zhu L, Baker SS, Wriston K, Torretta S, Stewart S, Siegner J, Osmack P, King D, Jain A, Derdoy J, Barlow S, Whitington PF, Sharda L, Rigsby C, Mohammad S, Kirwan E, Fishbein MH, Amsden K, Scheimann A, Kafka K, Subbarao G, Sandrasegaran K, Munson S, Molleston JP, Klipsch A, Cummings OW, Bozic M, Vos M, Raviele N, Cruz Munos J, Karpen S, Cleeton R, Alazraki A, Reynoso E, Mencin A, Lefkowitch JH, Lavine JE, Behr G, Xanthakos S, Towbin A, Podberesky D, Lake K, Kohli R, DeVore S, Cecil K, Bramlage K, Bernstein K, Mahabir R, Maldonado L, Krisnamurthy R, Himes R, Barlow S, Abrams SH, NASH CRN, Doo E, Tonascia J, Clark JM, Van Natta ML, Kleiner DE, Brunt EM, Murray KF, Jain AK, Whitington PF, Molleston JP, Karpen SJ, Vos MB, Barlow SE, Kohli R, Xanthakos SA, Neuschwander-Tetri BA, Wilson LA, Lavine JE, Schwimmer JB, Rosenthal P, Sherker A, Robuck PR, Hoofnagle JH, Doo EC, Brown S, May KP, Miriel L, Sternberg A, Tonascia J, Van Natta M, Vaughn I, Wilson L, Yates K, Hallinan E, Isaacson M, Donithan M, Clark JM, Belt P, Torrance R, Kleiner DE, Fowler K, Brunt EM, Young M, Yeh M, Otto R, Murray K, Hsu E, Horslen S, Cooper K, Tsai P, Rosenthal P, Perito ER, Langlois C, Gill R, Fleck S, Ferrell LD, Courtier J, Aouizerat B, Villarreal MD, Ugalde-Nicalo P, Sirlin C
Studies: Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children

Abstract

No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD.

Home chevron_right Publications chevron_right In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Abstract